By substantially decreasing TTR production, vutrisiran aims to slow down or halt the progression of ATTRv amyloidosis, thus alleviating the debilitating symptoms associated with the deposition of amyloid fibrils throughout the body. The gene discussed is TTR; the disease is amyloidosis.